Not SpaceX. Not Blue Origin. The Space Titan That Morgan Stanley Calls an Undervalued Launch Play.
Morgan Stanley highlights Rocket Lab (RKLB) as an undervalued space stock with a $105 price target. The company has a $2.36B backlog and signed a 20-mission contract. It's expanding into space services via Iridium acquisition. RKLB trades at $75, with $769M revenue and a P/S ratio of 50, but is not profitable.
How this was made

The 30-second read
Why it matters
The 20‑mission deal and Iridium acquisition provide a clear growth runway, potentially lifting the stock.
Market read
New contract and acquisition could re‑price Rocket Lab’s growth prospects in the space sector.
What to watch
Execution risk on the Neutron rocket and integration of Iridium may delay benefits.
Background
Rocket Lab is positioning itself as a broader space‑services provider beyond its Electron launch vehicle.
Ticker impact
Rocket Lab signed a 20‑mission contract with Synspective worth $2.36 billion and is finalising its acquisition of Iridium Communications.
likely upside as investors price in higher future launch and satellite service revenue
Contract size and acquisition are material new facts that can boost growth expectations.
Market effects
strengthens the commercial launch segment and may pressure peers like SpaceX and Blue Origin.
U.S. space‑tech equities could see modest gains.
adds to overall optimism for the growing space services market.
Counterpoint
High valuation multiples and cash burn could limit upside despite new contracts.
Key entities
- companyRocket Lab
U.S. listed launch services provider (ticker RKLB).
- companySynspective
Customer signing the 20‑mission contract.
- companyIridium Communications
Satellite communications firm being acquired.




